Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase

Kengo Ogawa, Takeshi Hara, Masahito Shimizu, Soranobu Ninomiya, Junji Nagano, Hiroyasu Sakai, Masato Hoshi, Hiroyasu Ito, Hisashi Tsurumi, Kuniaki Saito, Mitsuru Seishima, Takuji Tanaka, Hisataka Moriwaki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The escape of preneoplastic cells from the immune system, which is caused by immune tolerance, occurs during the development of several types of tumors. Indoleamine 2,3-dioxygenase (IDO) plays a critical role in the induction of immune tolerance. In the present study we investigated the effects of 1-methyltryptophan (1-MT), an IDO inhibitor, and (-1;)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the development of azoxymethane (AOM)-induced colonic preneoplastic lesions by focusing on the inhibition of IDO. To induce colonic premalignant lesions, male F344 rats were injected with AOM (20 mg/kg body weight, s.c.) once a week for 2 weeks. They also received 0.2% 1-MT or 0.1% EGCG in their drinking water for 4 weeks, starting 1 week before the first dose of AOM. Both 1-MT and EGCG significantly decreased the total number of aberrant crypt foci and β-catenin-accumulated crypts, which overexpressed IDO protein. Treatment with EGCG decreased IDO mRNA expression in both the colonic epithelium and stroma of rats induced by AOM. The AOM-induced increase in cyclooxygenase-2 mRNA expression in the colonic stroma was significantly decreased by EGCG. Furthermore, AOM-induced increases in IDO activity in the serum and stroma were significantly inhibited by 1-MT and EGCG. Inhibition of IDO activity by 1-MT and EGCG was also observed in cell-free assays. These findings suggest that upregulation of IDO activity is observed in the early stages of colon carcinogenesis and that the use of IDO inhibitors, such as 1-MT and EGCG, which suppress the occurrence of colonic preneoplastic lesions, could be a novel strategy for the chemoprevention of colon cancer.

Original languageEnglish
Pages (from-to)951-958
Number of pages8
JournalCancer Science
Volume103
Issue number5
DOIs
Publication statusPublished - 01-05-2012

Fingerprint

Azoxymethane
Indoleamine-Pyrrole 2,3,-Dioxygenase
Immune Tolerance
Aberrant Crypt Foci
1-methyltryptophan
Catenins
Messenger RNA
epigallocatechin gallate
Catechin
Inbred F344 Rats
Chemoprevention
Tea
Cyclooxygenase 2
Drinking Water
Colonic Neoplasms
Immune System
Colon
Carcinogenesis
Up-Regulation
Epithelium

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ogawa, Kengo ; Hara, Takeshi ; Shimizu, Masahito ; Ninomiya, Soranobu ; Nagano, Junji ; Sakai, Hiroyasu ; Hoshi, Masato ; Ito, Hiroyasu ; Tsurumi, Hisashi ; Saito, Kuniaki ; Seishima, Mitsuru ; Tanaka, Takuji ; Moriwaki, Hisataka. / Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. In: Cancer Science. 2012 ; Vol. 103, No. 5. pp. 951-958.
@article{da8c317f95d24ecb8c8acdb82a15f95f,
title = "Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase",
abstract = "The escape of preneoplastic cells from the immune system, which is caused by immune tolerance, occurs during the development of several types of tumors. Indoleamine 2,3-dioxygenase (IDO) plays a critical role in the induction of immune tolerance. In the present study we investigated the effects of 1-methyltryptophan (1-MT), an IDO inhibitor, and (-1;)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the development of azoxymethane (AOM)-induced colonic preneoplastic lesions by focusing on the inhibition of IDO. To induce colonic premalignant lesions, male F344 rats were injected with AOM (20 mg/kg body weight, s.c.) once a week for 2 weeks. They also received 0.2{\%} 1-MT or 0.1{\%} EGCG in their drinking water for 4 weeks, starting 1 week before the first dose of AOM. Both 1-MT and EGCG significantly decreased the total number of aberrant crypt foci and β-catenin-accumulated crypts, which overexpressed IDO protein. Treatment with EGCG decreased IDO mRNA expression in both the colonic epithelium and stroma of rats induced by AOM. The AOM-induced increase in cyclooxygenase-2 mRNA expression in the colonic stroma was significantly decreased by EGCG. Furthermore, AOM-induced increases in IDO activity in the serum and stroma were significantly inhibited by 1-MT and EGCG. Inhibition of IDO activity by 1-MT and EGCG was also observed in cell-free assays. These findings suggest that upregulation of IDO activity is observed in the early stages of colon carcinogenesis and that the use of IDO inhibitors, such as 1-MT and EGCG, which suppress the occurrence of colonic preneoplastic lesions, could be a novel strategy for the chemoprevention of colon cancer.",
author = "Kengo Ogawa and Takeshi Hara and Masahito Shimizu and Soranobu Ninomiya and Junji Nagano and Hiroyasu Sakai and Masato Hoshi and Hiroyasu Ito and Hisashi Tsurumi and Kuniaki Saito and Mitsuru Seishima and Takuji Tanaka and Hisataka Moriwaki",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1349-7006.2012.02237.x",
language = "English",
volume = "103",
pages = "951--958",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

Ogawa, K, Hara, T, Shimizu, M, Ninomiya, S, Nagano, J, Sakai, H, Hoshi, M, Ito, H, Tsurumi, H, Saito, K, Seishima, M, Tanaka, T & Moriwaki, H 2012, 'Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase', Cancer Science, vol. 103, no. 5, pp. 951-958. https://doi.org/10.1111/j.1349-7006.2012.02237.x

Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. / Ogawa, Kengo; Hara, Takeshi; Shimizu, Masahito; Ninomiya, Soranobu; Nagano, Junji; Sakai, Hiroyasu; Hoshi, Masato; Ito, Hiroyasu; Tsurumi, Hisashi; Saito, Kuniaki; Seishima, Mitsuru; Tanaka, Takuji; Moriwaki, Hisataka.

In: Cancer Science, Vol. 103, No. 5, 01.05.2012, p. 951-958.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase

AU - Ogawa, Kengo

AU - Hara, Takeshi

AU - Shimizu, Masahito

AU - Ninomiya, Soranobu

AU - Nagano, Junji

AU - Sakai, Hiroyasu

AU - Hoshi, Masato

AU - Ito, Hiroyasu

AU - Tsurumi, Hisashi

AU - Saito, Kuniaki

AU - Seishima, Mitsuru

AU - Tanaka, Takuji

AU - Moriwaki, Hisataka

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The escape of preneoplastic cells from the immune system, which is caused by immune tolerance, occurs during the development of several types of tumors. Indoleamine 2,3-dioxygenase (IDO) plays a critical role in the induction of immune tolerance. In the present study we investigated the effects of 1-methyltryptophan (1-MT), an IDO inhibitor, and (-1;)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the development of azoxymethane (AOM)-induced colonic preneoplastic lesions by focusing on the inhibition of IDO. To induce colonic premalignant lesions, male F344 rats were injected with AOM (20 mg/kg body weight, s.c.) once a week for 2 weeks. They also received 0.2% 1-MT or 0.1% EGCG in their drinking water for 4 weeks, starting 1 week before the first dose of AOM. Both 1-MT and EGCG significantly decreased the total number of aberrant crypt foci and β-catenin-accumulated crypts, which overexpressed IDO protein. Treatment with EGCG decreased IDO mRNA expression in both the colonic epithelium and stroma of rats induced by AOM. The AOM-induced increase in cyclooxygenase-2 mRNA expression in the colonic stroma was significantly decreased by EGCG. Furthermore, AOM-induced increases in IDO activity in the serum and stroma were significantly inhibited by 1-MT and EGCG. Inhibition of IDO activity by 1-MT and EGCG was also observed in cell-free assays. These findings suggest that upregulation of IDO activity is observed in the early stages of colon carcinogenesis and that the use of IDO inhibitors, such as 1-MT and EGCG, which suppress the occurrence of colonic preneoplastic lesions, could be a novel strategy for the chemoprevention of colon cancer.

AB - The escape of preneoplastic cells from the immune system, which is caused by immune tolerance, occurs during the development of several types of tumors. Indoleamine 2,3-dioxygenase (IDO) plays a critical role in the induction of immune tolerance. In the present study we investigated the effects of 1-methyltryptophan (1-MT), an IDO inhibitor, and (-1;)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the development of azoxymethane (AOM)-induced colonic preneoplastic lesions by focusing on the inhibition of IDO. To induce colonic premalignant lesions, male F344 rats were injected with AOM (20 mg/kg body weight, s.c.) once a week for 2 weeks. They also received 0.2% 1-MT or 0.1% EGCG in their drinking water for 4 weeks, starting 1 week before the first dose of AOM. Both 1-MT and EGCG significantly decreased the total number of aberrant crypt foci and β-catenin-accumulated crypts, which overexpressed IDO protein. Treatment with EGCG decreased IDO mRNA expression in both the colonic epithelium and stroma of rats induced by AOM. The AOM-induced increase in cyclooxygenase-2 mRNA expression in the colonic stroma was significantly decreased by EGCG. Furthermore, AOM-induced increases in IDO activity in the serum and stroma were significantly inhibited by 1-MT and EGCG. Inhibition of IDO activity by 1-MT and EGCG was also observed in cell-free assays. These findings suggest that upregulation of IDO activity is observed in the early stages of colon carcinogenesis and that the use of IDO inhibitors, such as 1-MT and EGCG, which suppress the occurrence of colonic preneoplastic lesions, could be a novel strategy for the chemoprevention of colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=84862808949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862808949&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02237.x

DO - 10.1111/j.1349-7006.2012.02237.x

M3 - Article

C2 - 22320717

AN - SCOPUS:84862808949

VL - 103

SP - 951

EP - 958

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -